» Articles » PMID: 25734140

Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-limited Settings

Overview
Date 2015 Mar 4
PMID 25734140
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Amphotericin B is the preferred treatment for cryptococcal meningitis, but it has cumulative severe side effects, including nephrotoxicity, hypokalemia, and hypomagnesemia. Amphotericin-induced severe hypokalemia may predispose the patient to cardiac arrhythmias and death, and there is very little data available regarding these toxicities in resource-limited settings. We hypothesized that standardized electrolyte management during amphotericin therapy is essential to minimize toxicity and optimize survival in sub-Saharan Africa.

Methods: Human immunodeficiency virus-infected, antiretroviral therapy naive adults with cryptococcal meningitis were prospectively enrolled at Mulago Hospital in Kampala, Uganda in 3 sequential cohorts with amphotericin B deoxycholate induction treatment. Intravenous fluid use was intermittent in 2001-2002, and universal in 2006-2012. In 2001-2009, serum potassium (K(+)) was monitored on days 1, 7, and 14 of treatment with replacement (K(+), Mg(2+)) per clinician discretion. In 2011-2012, K(+) was measured on days 1, 5, and approximately every 48 hours thereafter with universal electrolyte (K(+), Mg(2+)) supplementation and standardized replacement. Clinical outcomes were retrospectively compared between fluid and electrolyte management strategies.

Results: With limited intravenous fluids, the 14-day survival was 49% in 2001-2002. With universal intravenous fluids, the 30-day survival improved to 62% in 2006-2010 (P = .003). In 2011-2012, with universal supplementation of fluids and electrolytes, 30-day cumulative survival improved to 78% (P = .021 vs 2006-2010 cohort). The cumulative incidence of severe hypokalemia (<2.5 mEq/L) decreased from 38% in 2010 to 8.5% in 2011-2012 with universal supplementation (P < .001).

Conclusions: Improved survival was seen in a resource-limited setting with proactive fluid and electrolyte management (K(+), Mg(2+)), as part of comprehensive amphotericin-based cryptococcal therapy.

Citing Articles

The evolution of HIV-associated cryptococcal meningitis in Uganda from 2010 to 2022.

Walukaga S, Fieberg A, Musubire A, Tugume L, Ssebambulidde K, Kagimu E Med Mycol. 2025; 63(1).

PMID: 39779301 PMC: 11718514. DOI: 10.1093/mmy/myae115.


Using single-dose liposomal amphotericin B for cryptococcal meningitis induction therapy: nurse pearls and practical perspectives.

Ndyetukira J, Kwizera R, Ahimbisibwe C, Namujju C, Meya D Wellcome Open Res. 2024; 9:253.

PMID: 39386968 PMC: 11462120. DOI: 10.12688/wellcomeopenres.21450.1.


Machine learning-based prognostic prediction for hospitalized HIV/AIDS patients with cryptococcus infection in Guangxi, China.

Zhan B, Wei W, Xie Z, Meng S, Bao X, He X BMC Infect Dis. 2024; 24(1):1121.

PMID: 39379851 PMC: 11459777. DOI: 10.1186/s12879-024-10013-y.


Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study.

Gakuru J, Kagimu E, Dai B, Okurut S, Nsangi L, Bahr N Clin Infect Dis. 2024; 80(2):417-424.

PMID: 39180324 PMC: 11848271. DOI: 10.1093/cid/ciae413.


Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV-Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers.

Meya D, Nalintya E, Skipper C, Kirumira P, Ayebare P, Naluyima R Clin Infect Dis. 2024; 80(1):129-136.

PMID: 39044381 PMC: 11797045. DOI: 10.1093/cid/ciae266.


References
1.
Jackson A, Nussbaum J, Phulusa J, Namarika D, Chikasema M, Kanyemba C . A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS. 2012; 26(11):1363-70. PMC: 3776948. DOI: 10.1097/QAD.0b013e328354b419. View

2.
Perfect J, Dismukes W, Dromer F, Goldman D, Graybill J, Hamill R . Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010; 50(3):291-322. PMC: 5826644. DOI: 10.1086/649858. View

3.
Girmenia C, Gentile G, Micozzi A, Martino P . Nephrotoxicity of amphotericin B desoxycholate. Clin Infect Dis. 2001; 33(6):915-6. DOI: 10.1086/322716. View

4.
Park B, Wannemuehler K, Marston B, Govender N, Pappas P, Chiller T . Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009; 23(4):525-30. DOI: 10.1097/QAD.0b013e328322ffac. View

5.
Bamba A, Jadhav M, Prabhu R, Ray S, Gogtay N, Jijina F . Refractory hypokalemia due to conventional amphotericin B in patients with leukemia. Indian J Cancer. 2009; 46(1):76-7. DOI: 10.4103/0019-509x.48605. View